Adlbrecht, C. and Breyer, E. and Gartlehner, G. and Guba, B. (2008): Selective Cell Apheresis in Inflammatory Bowel Disease. Decision Support Document 11.
This is the latest version of this item.
|PDF (selective cell apheresis - decision support document #11) - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
Selective Cell Apheresis (SCA)
Inflammatory bowel disease (Crohn's disease and colitis ulcerosa) are usually treated with antiinflammatory drugs or by surgical interventions. SCA is a subtype of apheresis where leukocytes are removed to reduce the inflammation. In a systematic search for available evidence for efficacy and safety of this intervention 4 randomised controlled studies as well as 8 uncontrolled interventional studies complied to the inclusion criteria. Although all of the studies present weakness of methodological quality, a nett benefit for the treatment of Colitis ulcerosa can be assumed. Therefore a restricted recommendation for the intervention of SCA can be made.
|Item Type:||Decision Support Document|
|Keywords:||selective cell adsorption leukocyte apheresis apheresis Morbus Crohn Colitis ulcerosa|
|Subjects:||WI Digestive system > WI 400-560 Intestines|
|Series Name:||Decision Support Document|
|Deposited on:||09 Aug 2008 12:57|
|Last Modified:||07 Nov 2008 19:17|
Available Versions of this Item
- (deposited 03 Sep 2008 11:06)
- Selective Cell Apheresis in Inflammatory Bowel Disease (deposited 09 Aug 2008 12:57) [Currently Displayed]
Repository Staff Only: item control page